Over the past 10 years, PARP inhibitors, immunotherapy and antibody drug conjugates have changed the treatment landscape of gynaecologic cancers, providing options for patients beyond chemotherapy.
Most of the recent FDA approvals for treating patients with gynaecologic malignancies are based on biomarkers. In ovarian cancer, germline genetic testing (patient’s blood or saliva) or somatic profiling (next-generation sequencing of a patient’s tumor) can focus on several biomarkers. For example, it can identify BRCA and homologous recombination deficiency — which occurs in approximately 50% of patients with ovarian cancers and can be treated with PARP inhibitors — and Lynch syndrome, which is a mismatch repair deficiency.
https://www.curetoday.com/view/steering-the-treatment-of-gynecologic-cancers-with-biomarkers
Lynch Syndrome Ireland 